.AstraZeneca execs say they are "not worried" that the failing of tozorakimab in a period 2 constant...
.Welcome to this week's Chutes & Ladders, our summary of considerable management hirings, firings...
.After disclosing programs to reach the U.S. social markets less than a month ago, Zenas Biopharma a...
.Psyence Biomedical is spending $500,000 in reveals to acquire fellow psilocybin-based biotech Clair...
.5 months after signing off on Power Rehabs' Pivya as the first new procedure for straightforward ur...